Karyopharm Therapeutics (KPTI) Accumulated Expenses (2012 - 2025)

Karyopharm Therapeutics has reported Accumulated Expenses for 14 years, with the latest figure at $10.3 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Expenses fell 25.66% year-over-year to $10.3 million; the trailing twelve-month figure through Dec 2025 stood at $10.3 million (down 25.66% YoY), and the FY2025 full-year result was $10.3 million, down 25.66% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $10.3 million, down from $66.3 million in the prior quarter.
• The five-year high for Accumulated Expenses was $66.3 million in Q3 2025, with the low at $10.3 million in Q4 2025.
• Historically, Accumulated Expenses has averaged $46.0 million across 5 years, with a median of $54.0 million in 2021.
• Annual changes were most pronounced in 2021 — Accumulated Expenses surged 60.71% — and 2025, when it dropped 25.66%.
• Karyopharm Therapeutics' Accumulated Expenses stood at $19.7 million in 2021, then fell by 0.31% to $19.6 million in 2022, then decreased by 15.87% to $16.5 million in 2023, then decreased by 15.72% to $13.9 million in 2024, then retreated by 25.66% to $10.3 million in 2025.
• The last three Accumulated Expenses figures came in at $10.3 million (Q4 2025), $66.3 million (Q3 2025), and $62.9 million (Q2 2025), per Business Quant data.